Procainamide Hci Injection, Solution
Product Images NDC 51662-1334

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Procainamide Hci (NDC 51662-1334). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51662 1334 2 Serialized Pouch Label

This is a description of a medication called Procainamide HCL Injection, which is administered through intravenous or intramuscular use. The medication is contained in a 1gram/10mL vial with a total content of 100mg/mL. Its packaging has an NDC code of 51662-1334-2, lot number 123456, and expiry date of 2036-681-81. The typical dosage is available in the insert. The medication should not be used if it appears darker than slightly yellow or discolored in any other way. The manufacturer is HF AcquisitionCo., LLC, based in Mukilteo, WA.*

FDA Label Image

51662 1334 3 Serialized Case Label

This is a description of Procainamide HCL Injection, USP. Each vial contains 1 gram/1 mL (100mg/mL) and is sold in a box of 25. The NDC number is 51662-1334-3, and the lot number is 123456 with an expiration date of 2036-081-81. It is for intravenous or intramuscular use, and caution is advised for those with allergies to sulfites. The usual dosage can be found in the insert, and the manufacturer is HFAcquisitionCo., LLC located in Mukilteo, WA. This product is only available by prescription.*

FDA Label Image

51662 1334 3 Serialized Case Labeling

FDA Label Image

Box Label (Box Label)

This is a description of a medication called "PROCAINAMIDE HYDROCHLORIDE Injection, USP". The product contains 1 gram of procainamide hydrochloride per 10 mL of solution, with each mL also containing 100 mg of procainamide hydrochloride, 1 mg of methylparaben and 0.8 mg of sodium metabisulfite. The medication is sterile, nonpyrogenic, and for intravenous use after dilution. The text includes a warning that the medication contains Metabi and one should not use it if it is discolored or darker than slightly yellow. The text also provides instructions for use, dosage, and storage of the medication.*

FDA Label Image

D1 (Dosage And Administration)

This is a chart indicating different dilutions and rates for intravenous infusion of Procainamide Hydrochloride Injection, USP. The chart suggests the initial concentration and volume to be added for procainamide infusion, loading, maintenance, and infusion rates. The maintenance infusion rates depend on factors such as body weight, renal elimination rate, and steady-state plasma level to control arhythmia. The final volume should be made up with 5% Dextrose Injection, USP. It is crucial to monitor the flow rate of the infusion to avoid high plasma levels and hypotension. Further details can be found under "Dosage and Administration."*

FDA Label Image

How Supplied (How Supplied)

This text contains information on two different pharmaceutical products. The first product has an NDC number of 0409-1902-01 and is packaged in a 10 mL flip-top vial with a concentration of 100mg/mL. The second product has an NDC number of 0409-1903-01 and is packaged in a 2 mL flip-top vial with a concentration of 500 mg/mL.*

FDA Label Image

Logo (Logo)

FDA Label Image

Serialized Box (Serialized Box)

FDA Label Image

Structure (Structure Desc)

FDA Label Image

Vial Label (Vial Label)

This is a 10 mL multiple-dose bottle of Procainamide HCl injection, USP. Each mL of the solution contains 100 mg of procainamide HCl, 1 mg of methylparaben as a preservative, and 0.8 mg of sodium metabisulfite. The solution may contain hydrochloric acid and/or sodium hydroxide for pH adjustment. It is important not to use the injection if it appears darker than slightly yellow or is discolored in any other way. The injection also contains metabisulfites. This product is manufactured by Hospira, Inc. in Lake Forest, IL.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.